Exagen Inc. (XGN) Tops Q2 EPS by 50c; offers outlook

Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of $0.16, $0.50 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.13 million.

GUIDANCE:

Exagen Inc. sees FY2024 revenue of $57 million, versus the consensus of $55.75 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley Private Credit Fund Caps Redemptions At 5%
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook